Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Broad, John ^a   Maurel, Damien ^b   Kung, Victor W S ^a   Hicks, Gareth A ^c,f   Schemann, Michael ^d   Barnes, Michael R ^a   Kenakin, Terrence P ^e   Granier, Sébastien ^b   Sanger, Gareth J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIV MONTPELLIER   (France)

^c Tioga Pharmaceuticals Inc   (United States)

^d Human Biology   (Germany)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ASIMADOLINE; KAPPA OPIATE RECEPTOR; PYRROLIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL; DRUG DESIGN; HEK293 CELL LINE; HUMAN; INTESTINE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

ACETAMIDES; ANIMALS; DRUG DESIGN; HEK293 CELLS; HUMANS; INTESTINES; MICE; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 84981276002     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30797     Document Type: Article

References (70)

1. Zhou, L. et al. Development of functionally selective, small molecule agonists at kappa opioid receptors. J. Biol. Chem. 288, 36703-36716 (2013).
2. Bourgeois, C. et al. Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted-opioid receptor agonists. J. Med. Chem. 57, 6845-6860 (2014).
3. Cheng, M. F. et al. Discovery, structure-activity relationship studies, anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists. Bioorg. Med. Chem. 22, 4694-4703 (2014).
4. White, K. L. et al. Identification of novel functionally selective-opioid receptor scaffolds. Mol. Pharmacol. 85, 83-90 (2014).
5. Rivière, P. J.-M. Peripheral kappa-opioid agonists for visceral pain. Br. J. Pharmacol. 141, 1331-1334 (2004).
6. Brandt, L. J. et al. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 104, S1-S35 (2009).
7. Allescher, H. D., Ahmad, S., Classen, M., Daniel, E. E. Interaction of trimebutine and Jo-1196 (fedotozine) with opioid receptors in the canine ileum. J. Pharmacol. Exp. Ther. 257, 836-842 (1991).
8. Barber, A. et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br. J. Pharmacol. 113, 1317-1327 (1994).
9. Barber, A. et al. Central and peripheral actions of the novel-opioid receptor agonist, EMD 60400. Br. J. Pharmacol. 111, 843-851 (1994).
10. Gottschlich, R., Krug, M., Barber, A., Devant, R. M. Kappa opioid activity of the four stereoisomers of the peripherally selective kappa-agonists EMD 60,400 and EMD 61,753. Chirality 6, 685-689 (1994).
11. Dapoigny, M., Abitbol, J. L., Fraitag, B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci. 40, 2244-2248 (1995).
12. Delvaux, M. et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distension in patients with irritable bowel syndrome (IBS). Gastroenterol. 116, 38-45 (1999).
13. Delvaux, M. et al. Effect of asimadoline, a opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 20, 237-246 (2004).
14. Mangel, A. W. et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 28, 239-249 (2008).
15. Szarka, L. et al. Efficacy of on-demand asimadoline, a peripheral-opioid agonist, in females with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 5, 1268-1275 (2007).
16. Vardy, E. et al. Chemotype-selective modes of action of-opioid receptor agonists. J. Biol. Chem. 288, 34470-34483 (2013).
17. Kenakin, T. The effective application of biased signalling to new drug discovery. Mol. Pharmacol. 88, 1055-1061 (2015).
18. Wei, L. N., Hu, X., Bi, J., Loh, H. Post-transcriptional regulation of mouse kappa-opioid receptor expression. Mol. Pharmacol. 57, 401-408 (2000).
19. Wei, L.-N., Law, P.-Y., Loh, H. H. Post-transcriptional regulation of opioid receptors in the nervous system. Front. Biosci. 9, 1665-1679 (2012).
20. Sanger, G. J., Holbrook, J. D.,rews, P. L. R. The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol. Sci. 32, 402-409 (2011).
21. Sanger, G. J., Broad, J., Kung, V., Knowles, C. H. Translational Neuropharmacology: The use of human isolated gastrointestinal tissues. Br. J. Pharmacol. 168, 28-43 (2013).
22. Culpepper-Morgan, J. A., Holt, P. R., LaRoche, D., Kreek, M. J. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea-pig. Life Sci. 56, 1187-1192 (1995).
23. Bagnol, D., Mansour, A., Akil, H., Watson, S. J. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 81, 579-591 (1997).
24. Poonyachoti, S., Kulkarni-Narla, A., Brown, D. R. Chemical coding of neurons expressing delta-and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum Cell Tissue Res. 307, 23-33 (2002).
25. Pol, O., Palacio, J. R., Puig, M. M. The expression of delta-and kappa opioid receptor is enhanced during intestinal inflammation in mice. J. Pharmacol. Exp. Ther. 306, 455-462 (2003).
26. Bansinath, M., Ramabadran, K., Turndorf, H., Puig, M. M. Kappa-opiate agonist-induced inhibition of gastrointestinal transit in different strains of mice. Pharmacology 42, 97-102 (1991).
27. Schattauer, S. S. et al. Ligand directed signalling differences between rodent and human kappa opioid receptors. J. Biol. Chem. 287, 41595-41607 (2012).
28. Li, J., Li, J. G., Chen, C., Zhang, F., Liu-Chen, L. Y. Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl]benzeneacetamide-induced desensitization and phosphorylation between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 61, 73-84 (2002).
29. Saito, M. et al. Variants of-opioid receptor gene and mRNA in alcohol-preferring and alcohol-avoiding mice. Alcohol 29, 39-49 (2003).
30. Shaw, S. J., Carroll, J. A., Alcock, P., Main, B. G. ICI 204448: a-opioid agonist with limited access to the CNS. Br. J. Pharmacol. 96, 986-992 (1989).
31. Wattchow, D. et al. Regional variation in the neurochemical coding of the myenteric plexus of the human colon and changes in patients with slow transit constipation. Neurogastroenterol. Motil. 20, 1298-1305 (2008).
32. Burleigh, D. E., Trout, S. J. Morphine attenuates cholinergic nerve activity in human isolated colonic muscle. Br. J. Pharmacol. 88, 307-313 (1986).
33. Sanger, G. J., Tuladhar, B. R. The role of endogenous opiates in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol. Motil. 16 (Suppl 2), 38-45 (2004).
34. Kumar, V. et al. Synthesis and evaluation of novel peripherally restricted-opioid receptor agonists. Bioorg. Med. Chem. Lett. 15, 1091-1095 (2005).
35. Menzaghi, F., Spencer, R. H., Lewis, M. E., Chalmers, D. T. Development of the novel, peripherally-selective kappa opioid agonist CR665 for the treatment of acute pain. Abstr, 12th World Congress on Pain (International association for the study of pain), www.caratherapeutics.com/files/CARA-CR665-IASP-2008.pdf (2008).
36. Mangel, A. W., Hicks, G. A. Asimadoline and its potential for the treatment of diarrhoea-predominant irritable bowel syndrome: a review. Clin. Exp. Gastroenterol. 5, 1-10 (2012).
37. Su, X., Joshi, S. K., Kardos, S., Gebhart, G. F. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J. Neurophysiol. 87, 1271-1279 (2002).
38. Joshi, S. K., Su, X., Porreca, F., Gebhart, G. F. Kappa-opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action. J. Neurosci. 20, 5874-5879 (2000).
39. Joshi, S. K., Lamb, K., Bielefeldt, K., Gebhart, G. F. Arylacetamide kappa-opioid receptor agonists produce a tonic-and usedependent block of tetrodotoxin-sensitive and-resistant sodium currents in colon sensory neurons. J. Pharmacol. Exp. Ther 307, 367-372 (2003).
40. Broad, J. et al. Major ligand-dependent differences in efficacy between kappa opioid receptor agonists in human, but not mouse colon. Proc. Br. Pharmacol. Soc. at http://www.pA2online.org/abstracts/Vol11Issue3abst048P.pdf (2013).
41. Bassil, A., Murray, C., Dass, N. M., Muir, A., Sanger, G. J. Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. Eur. J. Pharmacol. 524, 138-144 (2005).
42. Portoghese, P. S., Lipkowski, A. W., Takemori, A. E. Binaltorphimine and nor-binaltorphamine, potent and selective-opioid receptor antagonists. Life Sci. 40, 1287-1292 (1987).
43. Takemori, A. E., Ho, B. Y., Naeseth, J. S., Portoghese, P. S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246, 255-258 (1988).
44. Broad, J. et al. Regional-and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br. J. Pharmacol. 167, 763-774 (2012).
45. Madabushi, S. et al. Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and classspecific functions. J. Biol. Chem. 279, 8126-8132 (2004).
46. McLaughlin, J. P., Xu, M., Mackie, K., Chavkin, C. Phosphorylation of a carboxyl-terminal serine within the kappa-opioid receptor produces desensitization and internalization. J. Biol. Chem. 278, 34631-34640 (2003).
47. Alexander, S. P. H. et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br. J. Pharmacol. 172, 5744-5869 (2015).
48. Borsodi, A. et al. Opioid receptors: receptor. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForwardobjectId= 318 (2014).
49. Yasuda, K. et al. Cloning and functional comparison of and opioid receptors from mouse brain. Proc. Natl. Acad. Sci. USA 90, 6736-6740 (1993).
50. Nakayama, S. et al. Regulatory role of enteric mu and kappa opioid receptors in the release of acetylcholine and norepinephrine from guinea-pig ileum. J. Pharmacol. Exp. Ther. 254, 792-798 (1990).
51. Cosentino, M. et al. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of and opioid receptor blockade and of chronic sympathetic denervation. Neurosci. Lett. 194, 185-188 (1995).
52. Giuliani, S., Lecci, A., Tramontana, M., Maggi, C. A. Role of opioid receptors in modulating cholinergic twitches in the circular muscle of guinea-pig colon. Br. J. Pharmacol. 119, 985-989 (1996).
53. Allescher, H. D., Storr, M., Brechmann, C., Hahn, A., Schusdziarra, V. Modulatory effect of endogenous and exogenous opioids on the excitatory reflex pathway of the ratileum. Neuropeptides 34, 62-68 (2000).
54. Shahbazian, A. et al. Involvement of mu-and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br. J. Pharmacol. 135, 741-750 (2002).
55. Angel, F., Chamouard, P., Klein, A., Martin, E. Opioid agonists modulate excitatory and inhibitory neurotransmission in human colon. Neurogastroenterol. Motil. 5, 289-297 (1993).
56. Chamouard, P., Klein, A., Martin, E., Adloff, M., Angel, F. Regulatory role of enteric kappa opioid receptor receptors in human colonic motility. Life Sci. 53, 1149-1156 (1993).
57. Adami, M., Bertaccini, G., Roncoroni, L., Cobianchi, F. Effect of fedotozine on human distal colon. Ital. J. Gastroenterol. 28, 441-446 (1996).
58. Coruzzi, G., Morini, G., Coppelli, G., Bertaccini, G. The contractile effect of fedotozine on guinea pig isolated intestinal cells is not mediated by kappa opioid receptors. Pharmacology 56, 281-284 (1998).
59. Schreibera, R., Bartoszykb, G. D., Kunzelmann, K. The-opioid receptor agonist asimadoline inhibits epithelial transport in mouse trachea and colon. Eur. J. Pharmacol. 503, 185-190 (2004).
60. Delgado-Aros, S. et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am. J. Physiol. 284, G558-G566 (2003).
61. DeWire, S. M. et al. A G protein-biased ligand at the-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344, 708-717 (2013).
62. Raehal, K. M., Walker, J. K., Bohn, L. M. Morphine side effects in beta-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314, 1195-1201 (2005).
63. Groer, C. E. et al. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71, 549-557 (2007).
64. Kang, M. et al. The role of ß-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea-pig gastrointestinal tract. J. Pharmacol. Exp. Ther. 340, 567-576 (2012).
65. Maguma, H. T., De, D. D., Bhave, S., Dewey, W. L., Akbarali, H. I. Specific localization of ß-arrestin2 in myenteric plexus of mouse gastrointestinal tract. PLoS ONE 9, e103894 (2014).
66. Pradhan, A. A. et al. Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function. J. Neurosci. 36, 3541-3551 (2016).
67. Kuo, A., Wyse, B. D., Meutermans, W., Smith, M. T. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. Br. J. Pharmacol. 172, 532-548 (2015).
68. Tallent, M., Dichter, M. A., Bell, G. I., Reisine, T. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells. Neuroscience 63, 1033-1040 (1994).
69. Black, J. W., Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. 220, 141-162 (1983).
70. Broad, J. et al. Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br. J. Pharmacol. 170, 1253-1261 (2013).